PCN56 Brentuximab Vedotin PLUS CHP in Frontline Systemic Anaplastic Large Cell Lymphoma (SALCL): Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Retreatment with Brentuximab Vedotin
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.193
https://www.valueinhealthjournal.com/article/S1098-3015(20)32449-9/fulltext
Title :
PCN56 Brentuximab Vedotin PLUS CHP in Frontline Systemic Anaplastic Large Cell Lymphoma (SALCL): Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Retreatment with Brentuximab Vedotin
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32449-9&doi=10.1016/j.jval.2020.08.193
First page :
Section Title :
Open access? :
No
Section Order :
10147